Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.350,00
0,25%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vanda Pharmaceuticals Inc (VNDA) Vanda Pharmaceuticals Inc (VNDA) Notizie

Vanda Pharmaceuticals Inc

VNDA
4,8598
0,0398 (0,83%)
04 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202415:13PRNUSVanda Pharmaceuticals Announces Orphan Drug Designation..
18/11/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202422:10EDGAR2Form 144 - Report of proposed sale of securities
12/11/202422:58PRNUSVanda Pharmaceuticals Announces Participation at November..
07/11/202413:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:16EDGAR2Form 8-K - Current report
06/11/202422:02PRNUSVanda Pharmaceuticals Reports Third Quarter 2024 Financial..
30/10/202421:30PRNUSVanda Pharmaceuticals to Announce Third Quarter 2024..
15/10/202414:00EDGAR2Form 8-K - Current report
15/10/202411:46IHMARKETNEWSEricsson Shares Surge 7% on Strong Earnings, Nvidia Drops..
14/10/202416:56PRNUSVanda Pharmaceuticals Confirms Receipt of Economically..
03/10/202423:00EDGAR2Form 8-K - Current report
19/9/202414:10EDGAR2Form 8-K - Current report
19/9/202413:00PRNUSFDA Declines to Approve Vanda's Marketing Application for..
11/9/202423:00PRNUSVanda Pharmaceuticals Announces Participation in the 2024..
04/9/202423:13PRNUSVanda Pharmaceuticals Announces Participation in the H.C...
29/8/202422:30PRNUSVanda Pharmaceuticals Announces Participation in the Wells..
08/8/202413:47EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
08/8/202413:29EDGAR2Form 8-K - Current report
01/8/202413:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202422:05EDGAR2Form 8-K - Current report
31/7/202422:01PRNUSVanda Pharmaceuticals Reports Second Quarter 2024 Financial..
29/7/202423:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/7/202423:21EDGAR2Form 144 - Report of proposed sale of securities
26/7/202415:19PRNUSVanda Pharmaceuticals to Announce Second Quarter 2024..
01/7/202414:01PRNUSFederal Court Allows Vanda's HETLIOZ® Patent Lawsuit to..
20/6/202402:48PRNUSVanda Pharmaceuticals Board of Directors Determines that..
13/6/202422:38EDGAR2Form 8-K - Current report
13/6/202416:02PRNUSVanda Pharmaceuticals Confirms Receipt of Revised..
06/6/202422:30EDGAR2Form 8-K - Current report
06/6/202415:24PRNUSVanda Pharmaceuticals Confirms Receipt of Unsolicited,..
30/5/202423:20PRNUSVanda Pharmaceuticals Announces Participation in the..
30/5/202422:48PRNUSVanda Pharmaceuticals Announces Completion of Transfer of..
29/5/202420:17PRNUSVanda Pharmaceuticals Announces Presentations at SLEEP 2024
24/5/202422:49EDGAR2Form 8-K - Current report
24/5/202422:46PRNUSVanda Pharmaceuticals Board of Directors Determines that..
24/5/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:31EDGAR2Form 8-K/A - Current report: [Amend]
21/5/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/5/202423:26EDGAR2Form 8-K - Current report
15/5/202414:45PRNUSVanda Pharmaceuticals Reports Positive Results from a Second..
13/5/202422:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/5/202423:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/5/202413:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:06EDGAR2Form 8-K - Current report
08/5/202422:01PRNUSVanda Pharmaceuticals Reports First Quarter 2024 Financial..
07/5/202422:51EDGAR2Form 8-K - Current report
Apertura: 4,88 Min: 4,79 Max: 4,9038
Chiusura: 4,82

La tua Cronologia

NASDAQ
VNDA
Vanda Pharmaceuticals
BIT
NSCIT581X0E8
InterAmerican Developmen...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network